Analyzing tumor samples to help enroll patients in early phase clinical trials
Official title: Molecular Characterization of Solid Tumors and Lymphomas to Optimize the Drug Development Process and Patients Enrollment in Early Phase Clinical Trials
Run by Oncology Institute of Southern Switzerland · NCT04510766 · Data updated 2026-11-12
This study is trying to see if analyzing tumor samples can help doctors find the right patients for early clinical trials for advanced cancers and lymphomas.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Oncology Institute of Southern Switzerland Academic / other |
| Locations | 1 site (Bellinzona) |
| Status | Recruiting |
| Started | October 1, 2020 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | November 18, 2025 |
| Trial ID | NCT04510766 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a histological diagnosis of advanced solid tumors or lymphomas who are potential candidates for early phase clinical trials.
✕Probably not a fit
Patients with other active malignancies or those with conditions that disqualify them from early phase clinical trials may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the role of molecular tumor profiling in facilitating patient enrollment in early phase clinical trials for advanced solid tumors and lymphomas. It consists of two parts: the first part involves analyzing archival tumor tissue from potential candidates to identify genomic alterations, while the second part assesses tumor tissue from patients already enrolled in trials to investigate gene expression and collect blood samples for future research. The study will utilize advanced genomic sequencing technologies to gather comprehensive data on tumor characteristics.
Why it matters
Potential benefit: If successful, this study could enhance the precision of patient matching for early phase clinical trials, potentially leading to better treatment outcomes.
How similar studies have gone: Other studies utilizing molecular profiling for patient enrollment in clinical trials have shown promising results, indicating that this approach is gaining traction in the field.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female patients age at least 18 years. 2. Patients with histological diagnosis of advanced solid tumor or lymphoma who are potential candidates for early phase clinical trials. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 4. Live expectancy of at least 6 months. 5. Availability of FFPE archival tumor tissue from previous surgery or diagnostic biopsy adequate for molecular analysis. 6. Ability to understand the patient information and study consent. Signed and dated written informed consent must be available before performing any study-related procedure. 7. Willing and able to comply with study procedures Exclusion Criteria: 1. Presence of any clinical (e.g. concomitant disease, clinically significant symptoms, or non-clinical (psychological or social) conditions that would not make the patient eligible for enrolment in an early phase clinical trial. 2. Any other active malignancy (other than the one for which the subject is being assessed for trial option) that is progressing or requiring active treatment with the exception of basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site.
Where it's running
-
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland Recruiting
Study contacts
- Principal investigator: Ilaria Colombo, MD — Oncology Institute of Southern Switzerlan
- Study coordinator: Ilaria Colombo, MD
- Email: ilaria.colombo@eoc.ch
- Phone: +41 (0)91 811 8194
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing a new drug for advanced solid tumors and lymphoma
This study is testing a new drug called BPI-371153 to see if it is safe and effective for people with advanced solid tumors or lymphoma that hasn’t responded to other treatments.
-
Testing T-1301 capsules for advanced solid tumors
This study is testing a new oral medication called T-1301 to see if it is safe and effective for people with advanced solid tumors, including lymphoma.
-
LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma
This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
SGT003 in people with advanced solid tumors
This early-phase study tests SGT003 in adults with advanced solid tumors to see if it is safe and tolerable and to get a first look at how it behaves in the body and any early signs of benefit.
-
YSCH-01 Nebulized Therapy for Lung Metastases in NSCLC and Advanced Solid Tumors
A first-in-human, early-phase study tests a nebulized therapy called YSCH-01 to see if it is safe and shows any signs of benefit for adults with NSCLC or other cancers that have spread to the lungs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.